Navigation Links
Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
Date:5/6/2008

United Therapeutics to Hold Investor Q&A Session Following Conclusion of

ATS Conference

SILVER SPRING, Md., May 6 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. today announced that data related to the four different routes of administration of the drug, treprostinil, for the treatment of pulmonary arterial hypertension will be presented at the annual meeting of the American Thoracic Society (ATS), to be held in Toronto, Ontario, beginning May 16th and ending May 21, 2008, including the first public presentation of the full data set from the TRIUMPH-1 study of inhaled treprostinil. Additional information concerning presentation topics and times may be accessed via the ATS conference website or at http://ir.unither.com/events.cfm.

United Therapeutics will host an investor Q&A session following the conclusion of the ATS conference at The Westin Harbour Castle, One Harbour Square, Toronto, Ontario, on May 21, 2008, at 5:00 pm EDT. Lewis Rubin, MD, Director of the Pulmonary Hypertension Program at the University of California San Diego, and Vallerie McLaughlin, MD, Director of the Pulmonary Hypertension Program at the University of Michigan, will participate in this Q&A session, which is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening ca
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
2. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
5. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
6. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
7. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
8. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
9. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
10. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
11. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2008)...clinical program to evaluate TAXUS(R) Element(TM) ...Stent, NATICK, Mass., Oct. 8 /PRNewswire-FirstCal...today announced that it has completed enrollment i...any,s third-generation,TAXUS(R) Element(TM) paclit...program has enrolled nearly 1,500 patients at 100 ...
(Date:10/7/2008)...DIEGO, Oct. 7 /- Prometheus Laborator...y announced findings from its,development of PROME...test,for irritable bowel syndrome (IBS). The findi...on of particular biomarkers in blood samples,betwe... these biomarkers,combined with a proprietary alg...
(Date:10/7/2008)...lts of FLEXX Trial Presented at the Osteoarthritis...ess, PARSIPPANY, N.J., Oct. 7 /- Fer...ts from the FLEXX Trial of Osteoarthritis of the,K...te), a highly pure,non-avian high molecular weight...is superior to intra-articular saline (IA-saline) ...
(Date:10/7/2008)... clinical study of adults, VYVANSE taken once-dail...in one week, PHILADELPHIA, Oct. 7 /PRNewswire-Fir...e global specialty biopharmaceutical company, toda...r issue of the Journal of,Clinical Psychiatry foun...ion Deficit Hyperactivity Disorder (ADHD) symptoms...
Breaking Medicine Technology:Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 1Tongji Hires German Based Dr Petri Consulting GmbH for Langdong Project 24446 2Psychemedics Corporation Announces Second Quarter Results 24442 1Psychemedics Corporation Announces Second Quarter Results 24442 2Psychemedics Corporation Announces Second Quarter Results 24442 3Psychemedics Corporation Announces Second Quarter Results 24442 4Psychemedics Corporation Announces Second Quarter Results 24442 5Arcadia Radiology Medical Group Chooses AMICAS 6758 1Arcadia Radiology Medical Group Chooses AMICAS 6758 2Arcadia Radiology Medical Group Chooses AMICAS 6758 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 1Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 2Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 3Emisphere Presents Dramatic Clinical Evidence Demonstrating New Approach to Vitamin B12 Supplementation 2718 4
...pyridopyrazine-urea derivative compound series sho...e valuable for cancer,treatment , , QUBEC C... (TSX: AEZ; Nasdaq:,AEZS), a global, pure play b...erapy and oncology, today presented an abstract,...e derivatives,with high selectivity for PI3K inh...
...SINESS WIRE)--Apr 17, 2007 - Alnylam,Pharmaceutica...cs,company, announced today at the American Associ...ng that it will advance a,systemically delivered R...iver cancer and potentially other solid tumors as ...erapeutic that is,designed to target vascular endo...
Other Medicine Technology:terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 2terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 3terna Zentaris Discloses First In Vitro Data for its PI3K,Inhibitors at the AACR Annual Meeting in Los Angeles 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 2Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 3Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 4Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer 5
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...'s National Eye Institute is seeking to raise glau... higher risk for the disease than others, the Cas...ans over age 60, blacks over age 40 and people wit...ace a higher risk for the disease. Five percent of...
...an article published in International Political So...ical pathologization of the Guantanamo detainees ,...etainment accredit the attempted suicides to the i...s the high prevalence of suicide attempts at the G...
... research to be published in BJOG: An Internationa...nk between the development of placenta praevia an...ncies of women who previously had a caesarean sect...as the implantation of the placenta over or near t...
...eaved families of firefighters who lost their live...eave a sigh of relief at last. Ontarios new labor ...cause of death in order to qualify for compensatio...hanges of regulations will identify eight types of...
Other Medicine News:Health News:Study Examines the Pathologization of Guantanamo Suicides 2Health News:Placental Problems in Women Linked With Caesarean Section 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 3
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer
...al growth system, combines orbital shaking, oxygen...r bacterial growth. It is designed for easy integr...Extractor. The uniquely engineered HT-MegaGrowTM h...akers. Plate-holding cassettes allow for high plat...
Inquire
Inquire
Medicine Products: